Desensitization to Growth Hormone-Releasing Factor (GRF) Is Associated with Down-Regulation of GRF-Binding Sites*
- 1 May 1986
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 118 (5) , 2045-2052
- https://doi.org/10.1210/endo-118-5-2045
Abstract
The time course, concentration dependence, and mechanism of rat anterior pituitary desensitization to GRF were studied. Chronic stimulation of cultures of rat anterior pituitary cells with rat GRF (rGRF) resulted in desensitization to a subsequent challenge with the peptide. Despite a slight enhancement of GH synthesis, prolonged exposure to GRF caused substantial depletion of cellular GH pools. As a result, acute secretory responses were markedly blunted. Depletion was accompanied by a time-dependent decrease in sensitivity to rGRF; GRF EC50 values for GH release of 0.5 nM rGRF-pretreated cells were 24.8 .+-. 6 (.+-. SEM) pM after 2 h, 46.2 .+-. 2.4 pM after 4 h, and 154.7 .+-. 31 pM after 8 h compared to 9.2 .+-. 0.6 pM for control cells. The process of desensitization was complete within 8 h, as cells pretreated for 24 h exhibited sensitivity of rGRF comparable to that of cells pretreated for 8 h. Desensitization was associated with a time-dependent decrease in rat anterior pituitary cell GRF-binding capacity; a 48% loss of binding sites was evident after a 2-h pretreatment with 0.5 nM rGRF, with a maximum loss occurring after 8. h. The dose of rGRF required to produce an attenuation of responsiveness did not completely correlate with the dose requirement for down-regulation of binding sites. The decrease in GRF-binding sites was not associated with any alteration of apparent Kd values, which were 0.36 (0.18-0.72) nM in control and 0.1 (0.01-0.82) nM after 8 h of exposure to 0.5 nM rGRF. Both the reduction in GRF-binding capacity and decreased sensitivity to GRF were reversible after 24 h, although cellular GH pools were not restored to control levels. These results suggest that rat anterior pitiuitary cells become desensitized to rGRF after chronic stimulation with a maximal concentration of the peptide. One mechanism for this decrease in apparent sensitivity to rGRF may be the pronounced reduction or down-regulation of GRF-binding sites.This publication has 28 references indexed in Scilit:
- HUMAN PANCREATIC GROWTH-HORMONE-RELEASING FACTOR SELECTIVELY STIMULATES GROWTH-HORMONE SECRETION IN MANThe Lancet, 1983
- INHIBITION OF THE PULSATILE SECRETION OF GROWTH HORMONE BY MONOCLONAL ANTIBODIES TO THE HYPOTHALAMIC GROWTH HORMONE RELEASING FACTOR (GRF)Endocrinology, 1982
- Growth Hormone-Releasing Factor from a Human Pancreatic Tumor That Caused AcromegalyScience, 1982
- Somatotroph HyperplasiaJournal of Clinical Investigation, 1982
- Somatocrinin (growth hormone releasing factor) in vitro bioactivity; Ca++ involvement, cAMP mediated action and additivity of effect with PGE2Biochemical and Biophysical Research Communications, 1982
- Physiological roles of somatocrinin and somatostatin in the regulation of growth hormone secretionBiochemical and Biophysical Research Communications, 1982
- Somatocrinin, growth hormone releasing factor, stimulates secretion of growth hormone in anesthetized ratsBiochemical and Biophysical Research Communications, 1982
- Desensitization to Gonadotropin-Releasing Hormone Observed in Superfused Pituitary Cells on Cytodex Beads*Endocrinology, 1981
- LIGAND: A versatile computerized approach for characterization of ligand-binding systemsAnalytical Biochemistry, 1980
- Hormonal regulation of peptide receptors and target cell responsesNature, 1979